What's in Janssen Korea, Ltd., Korea's pipeline?

Janssen Korea, Ltd., Korea has 16 drugs in our index: 13 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Janssen Korea, Ltd., Korea's portfolio?

Top competitors by shared drug class: KK Women's and Children's Hospital, Montefiore Medical Center, Cephalon, Johnson & Johnson Taiwan Ltd, Ain Shams University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/janssen-korea-ltd-korea.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Janssen Korea, Ltd., Korea — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Janssen Korea, Ltd., Korea pipeline: 13 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

13 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Oxybutynin chloride OROS	Oxybutynin chloride OROS	marketed
Propranolol booster	Propranolol booster	marketed
Topiramate Slow	Topiramate Slow	marketed
Tramadol Hydrochloride Plus Acetaminophen	Tramadol Hydrochloride Plus Acetaminophen	marketed
Fentanyl D-trans	Fentanyl D-trans	marketed
Fentanyl matrix	Fentanyl matrix	marketed
decitabine injection	decitabine injection	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)	Oncology
Tramadol HCl/acetaminophen Extended Release	Tramadol HCl/acetaminophen Extended Release	marketed	Opioid analgesic combination with NSAID alternative	Mu-opioid receptor; norepinephrine transporter; serotonin transporter	Pain Management
Tramadol hydrochloride/ Acetaminophen	Tramadol hydrochloride/ Acetaminophen	marketed	Opioid analgesic combination	Mu-opioid receptor; norepinephrine transporter; serotonin transporter	Pain Management
Hydromorphone HCl OROS	Hydromorphone HCl OROS	marketed	Opioid agonist	Mu-opioid receptor	Pain Management
Topiramate Standard	Topiramate Standard	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase	Neurology
Paliperdidone ER	Paliperdidone ER	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor	Psychiatry

Therapeutic area mix

Pain Management · 3
Pain management · 2
Neurology · 1
Oncology · 1
Psychiatry · 1
Psychiatry/Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

KK Women's and Children's Hospital · 2 shared drug classes
Montefiore Medical Center · 2 shared drug classes
Cephalon · 2 shared drug classes
Johnson & Johnson Taiwan Ltd · 2 shared drug classes
Ain Shams University · 2 shared drug classes
Labopharm Inc. · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
National Taiwan University Hospital · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Janssen Korea, Ltd., Korea:

Cite this brief

Drug Landscape (2026). Janssen Korea, Ltd., Korea — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-korea-ltd-korea. Accessed 2026-05-17.